Plain-English translation of NCT07298239 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 1 β Testing in a small group (usually 20β80 people) to find a safe dose and watch for side effects.
This study is testing a new type of immunotherapy called allogeneic CAR-NK cell therapy for men with metastatic castration-resistant prostate cancer β an advanced form of the disease that has stopped responding to standard treatments. The treatment uses specially engineered natural killer cells that are designed to recognize and attack prostate cancer cells. Researchers want to understand whether this medication is safe and whether it can help slow or stop cancer growth.
Many men with advanced prostate cancer eventually develop a form that no longer responds to hormone therapy, chemotherapy, or other current treatments, and they have limited options left. This trial exists because there is an urgent need for new, more effective treatment approaches for these patients.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You would receive the engineered immune cell treatment at the study center. The trial will closely monitor your safety and how well the treatment works, with blood tests and imaging scans to track your cancer and any side effects. This is an early-stage study with 15 participants total, so the exact schedule and number of visits will be determined by the research team, but you should expect regular follow-up appointments over several months.
AI-generated summary from trial data Β· Jun 12, 2026 Β· Not medical advice
China